[{"id":"345523f2-eb95-47c4-aa63-da74c79fb6fc","acronym":"EVEREST-1","url":"https://clinicaltrials.gov/study/NCT05736731","created_at":"2023-02-21T15:01:17.869Z","updated_at":"2024-07-02T16:35:10.811Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","source_id_and_acronym":"NCT05736731 - EVEREST-1","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A • CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • HLA-A*02","tags":["HLA-A • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e A2B530"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-04-09"}]